The role of antipsychotics in the management of fibromyalgia.
Calandre, Elena P, Rico-Villademoros, Fernando · CNS drugs · 2012 · DOI
Quick Summary
This review examines whether antipsychotic medications—drugs typically used to treat psychiatric conditions—might also help people with fibromyalgia manage pain, sleep problems, fatigue, and mood disturbances. The authors found that some antipsychotics, particularly quetiapine, have shown promise in small studies and case reports, though most research is preliminary and more rigorous testing is needed.
Why It Matters
ME/CFS and fibromyalgia share significant symptomatic overlap—chronic pain, fatigue, sleep disturbance, and cognitive dysfunction—and high comorbidity rates. Identifying novel pharmacological options with multi-system benefits (pain relief, sleep improvement, mood support) could expand treatment approaches for patients with these complex, difficult-to-treat conditions who may not tolerate or respond to first-line therapies.
Observed Findings
First- and second-generation antipsychotics demonstrate analgesic properties in experimental and human studies, though most human pain evidence involves older agents from decades ago.
Quetiapine, risperidone, and olanzapine show efficacy in anxiety disorders; quetiapine and aripiprazole demonstrate antidepressant activity.
Several antipsychotics (promethazine, olanzapine, quetiapine, ziprasidone) improve sleep parameters in healthy subjects.
Published case reports and series suggest therapeutic benefit with olanzapine and quetiapine, though olanzapine is limited by tolerability problems.
Two unpublished double-blind controlled trials presented at conferences suggest quetiapine may be an alternative treatment for fibromyalgia.
Quetiapine emerges as the most promising candidate based on preliminary controlled trial data and multiple therapeutic mechanisms.
Further rigorous research on antipsychotic efficacy in fibromyalgia is warranted and feasible.
Remaining Questions
What are the efficacy and safety profiles of antipsychotics in published randomized controlled trials for fibromyalgia?
What This Study Does Not Prove
This review does not establish efficacy of antipsychotics for fibromyalgia or ME/CFS; it identifies potential therapeutic targets based on mechanistic properties and preliminary clinical signals. The evidence base remains largely anecdotal, and published randomized controlled trials are minimal. Safety, optimal dosing, long-term tolerability, and applicability to ME/CFS specifically remain unproven.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.